继儿童粉、成人粉、母婴用品、宠物食品等新品类之后，贝因美又将触角伸向了大健康。5月7日，北京商报记者获悉，贝因美于近日宣布推出"生命伴侣系 列"益生菌新品。当奶粉市场竞争陷入内卷，贝因美意图通过益生菌这类高复购、强黏性的健康产品切入成人市场。但在日益激烈的全家营养赛道中，伊 利、飞鹤、佳贝艾特等奶粉巨头已经提前布局，并推出了全生命周期产品。贝因美加码益生菌赛道，能否讲出新故事，存在不小的难度。 据了解，此次贝因美首发推出的"生命伴侣系列"主要有生命伴侣1号、生命伴侣2号、生命伴侣10号，使用场景分别对应肠胃、肝脏和孕期。贝因美表示，新 品作为即食型益生菌，是肠道健康的"第四餐"，每颗含1001亿活菌+典藏专利菌株，聚焦精准营养、精确营养技术、个性化人群营养，活菌率能达到99%以 上。 欧睿国际数据显示，2022年以来，中国益生菌市场以每年11%－12%的速度快速增长。国际益生菌协会（IPA）分析认为，中国已经成为全球第二大益生菌 消费市场，到2028年市场规模有望接近2000亿元。 对于贝因美入局益生菌的优势，贝因美创始人兼首席科学家谢宏在发布会上表示，"贝因美进入益生菌赛道，是因为这是现代人基础健康的保障， ...

Core Viewpoint - The company, Beijia Clean Group Co., Ltd., reported a net profit of -77.32 million yuan for the year 2024, leading to a decision not to distribute dividends or increase capital reserves due to negative earnings [3][22][23]. Group 1: Financial Performance - In 2024, the company achieved operating revenue of 1.30 billion yuan, representing a year-on-year growth of 21.78% [15]. - The total assets of the company as of December 31, 2024, amounted to 2.14 billion yuan, an increase of 6.36% from the beginning of the year [15]. - The equity attributable to shareholders decreased by 20.35% to 994.95 million yuan compared to the beginning of the year [15]. Group 2: Market Overview - The oral hygiene market in China has shown significant growth potential, with the market size increasing from 38.8 billion yuan in 2017 to 52.2 billion yuan in 2021, achieving a compound annual growth rate (CAGR) of 7.7% [4]. - The market size for oral hygiene products in 2023 was 49.15 billion yuan, with an expected CAGR of 3.75% from 2023 to 2028, indicating a stable growth phase [4]. Group 3: Product Categories - Toothpaste and toothbrushes dominate the oral hygiene market, with toothpaste holding a market share of 51.0% and toothbrushes 31.0%, together accounting for 82.0% of the market [5]. - New product categories such as mouth sprays and electric toothbrushes are rapidly developing, with mouth sprays seeing a 3% year-on-year increase in online retail sales in 2024 [7]. Group 4: Strategic Decisions - The company plans not to distribute cash dividends or issue bonus shares for the year 2024, as the negative net profit does not allow for such distributions [21][22]. - The board of directors has proposed to authorize the board to formulate a mid-term dividend plan for 2025, contingent on meeting specific profit and cash flow conditions [25][28].

Core Insights - The article emphasizes the growing importance of human microbiota, referred to as the "second genome," in enhancing life quality and maintaining health balance [1][3] - Lifespace is positioned as a global leader in the probiotic market, aiming to redefine industry standards through scientific exploration and high-quality product offerings [3][4] Industry Overview - The human microbiome, particularly gut microbiota, plays a crucial role in digestion, immunity, and emotional regulation, comprising 78.67% of the human microbiome [1][3] - The probiotic market faces challenges such as low survival rates of live bacteria and inconsistent product efficacy, making it difficult for consumers to choose reliable products [3] Lifespace's Unique Approach - Lifespace's ACE research philosophy focuses on three core elements: High Activity (Alive), Patent Strains (Certified), and Effectiveness (Effective) [4][5] - The company employs advanced freeze-drying technology to maintain high activity levels of probiotics and uses high-density aluminum foil packaging to extend shelf life [4] - Lifespace has achieved a first-level certification for live bacteria rates from the China Nutrition Health Food Association, showcasing its excellence in probiotic survival rates [4] Research and Development - Lifespace invests significantly in proprietary strain development, including the well-known LPB27 strain, and collaborates with over 50 leading academic institutions globally for research and innovation [5][8] - The company has established long-term partnerships with renowned suppliers like BASF to ensure high-quality and stable raw materials for its products [8] Brand Engagement - Lifespace emphasizes emotional connections with consumers through initiatives like the "Every 'Y' Breakfast" event, promoting awareness of gut health while enjoying food [11][13] - The brand's efforts to create a warm and caring image have helped establish a more vibrant and relatable brand presence in consumers' minds [13] Future Outlook - Lifespace aims to continue leading the probiotic industry by leveraging scientific advancements and exploring the mysteries of microbiota to enhance human health [13]

Investment Rating - The report maintains a "Buy" rating for the company, expecting the stock price to outperform the industry index by over 15% in the next six months [4][16]. Core Insights - The company is a leader in the clinical probiotic sector and recently showcased its new weight management probiotics at the FIC2025 exhibition, highlighting its commitment to innovation in health products [1][2]. - The company has developed a rich resource library of over 40,000 strains of lactic acid bacteria, including more than 120 industrialized probiotics, which supports its competitive edge [2]. - The focus on B2B and B2C business models aims to expand customer base and enhance product offerings, with a strong emphasis on customized probiotic solutions [2][3]. Financial Summary - Revenue is projected to grow from 299 million yuan in 2023 to 469 million yuan by 2026, reflecting a compound annual growth rate (CAGR) of approximately 16.1% [1][3]. - Net profit is expected to increase from 93 million yuan in 2023 to 147 million yuan in 2026, with a notable growth rate of 17.3% in 2026 [1][3]. - The company's earnings per share (EPS) is forecasted to rise from 0.35 yuan in 2023 to 0.56 yuan in 2026, indicating a positive trend in profitability [1][3]. Market Position - The company has established a strong presence in the probiotic market, with a focus on clinical applications and innovative product development, positioning itself for future growth [2][3]. - The stock's current price-to-earnings (P/E) ratio is projected to decrease from 35.5 in 2023 to 22.5 in 2026, suggesting potential for valuation improvement as earnings grow [1][3].